mp.weixin.qq.com·· 6 hours agoPickScore55
Alcon Buys Neurotech for $550 Million in Second Ocular Cell Therapy Deal
In brief
Alcon has announced the acquisition of Neurotech Pharmaceuticals for an upfront payment of $550 million, with additional payments possible based on future commercial milestones, at an undisclosed cap. This is Alcon's second acquisition in ocular cell therapy. Neurotech's ENCELTO received FDA approval in March 2025 for idiopathic macular telangiectasia type 2 in adults.
Why it matters
Alcon acquires Neurotech for $550 million upfront with milestone payments, its second ocular cell therapy deal.
Source: mp.weixin.qq.com · mp.weixin.qq.com